Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cecilie Laurberg Christoffersen"'
Autor:
Piero Barbanti, Peter J. Goadsby, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background The multinational phase 3b DELIVER trial was designed to evaluate the efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures across 17 countries. In the placebo-controlled p
Externí odkaz:
https://doaj.org/article/7a81ae83aa2c4873bde25a68ab3a5515
Autor:
Peter J. Goadsby, Piero Barbanti, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling
Publikováno v:
European journal of neurology.
In the phase 3b, randomized, double-blind, placebo-controlled DELIVER clinical trial, eptinezumab reduced migraine frequency and headache in adults with two to four prior preventive treatment failures. Here the effect of eptinezumab on coinciding pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4efb865acc444cf17cfbf1d4d0704a3b
https://pubmed.ncbi.nlm.nih.gov/36583633
https://pubmed.ncbi.nlm.nih.gov/36583633
Autor:
Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling, Patricia Pozo-Rosich
Publikováno v:
Scientia
Chronic migraine; Episodic migraine; Eptinezumab Migraña crónica; Migraña episódica; Eptinezumab Migranya crònica; Migranya episòdica; Eptinezumab Background Migraine is a disabling neurological disease adversely affecting many aspects of life.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006909be91c162946f3b975daae3b4aa
https://doi.org/10.1177/03331024231170807
https://doi.org/10.1177/03331024231170807
Autor:
Peter Goadsby, Piero Barbanti, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Bjørn Sperling, Caroline Defawe Rajca
Publikováno v:
Revue Neurologique. 179:S41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ade0bdf6565020ab3dfc0cc1819f1c2e
https://doi.org/10.1016/j.neurol.2023.01.084
https://doi.org/10.1016/j.neurol.2023.01.084
Autor:
Messoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling
Publikováno v:
The Lancet. Neurology. 21(7)
The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and acceptable safety and tolerability in phase 3 trials, but benefits in the subpopulations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe4dab51f521a1ff81f270d49b590b48
https://pubmed.ncbi.nlm.nih.gov/36191321
https://pubmed.ncbi.nlm.nih.gov/36191321